carbamates has been researched along with Insulin Resistance in 24 studies
Insulin Resistance: Diminished effectiveness of INSULIN in lowering blood sugar levels: requiring the use of 200 units or more of insulin per day to prevent HYPERGLYCEMIA or KETOSIS.
| Excerpt | Relevance | Reference |
|---|---|---|
| " In this study, we used the frequently sampled intravenous glucose tolerance test (FSIGT) to evaluate the insulin sensitivity (IS), glucose sensitivity (SG), and acute insulin response after glucose load (AIRg) after 4 months treatment with either gliclazide or repaglinide." | 9.14 | Comparison of insulin sensitivity, glucose sensitivity, and first phase insulin secretion in patients treated with repaglinide or gliclazide. ( Chu, YM; Hsia, TL; Hsiao, FC; Hsieh, AT; Lee, LH; Lin, JD; Pei, C; Pei, D; Wang, K; Wu, CZ, 2010) |
| "In two separate double-blind, randomized, cross-over studies, we assessed the effects of a single dose of ritonavir (800 mg) and amprenavir (1200 mg) on insulin sensitivity (euglycemic hyperglycemic clamp) in healthy normal volunteers." | 9.12 | Effects of ritonavir and amprenavir on insulin sensitivity in healthy volunteers. ( Aweeka, F; Grunfeld, C; Lee, GA; Lo, JC; Mulligan, K; Rao, M; Schambelan, M; Schwarz, JM, 2007) |
| " During the first year of treatment, exenatide, in combination with metformin and repaglinide, led to a weight loss of 14 kg and fat mass and waist circumference were respectively reduced from 31 to 25." | 7.77 | Exenatide improves weight loss insulin sensitivity and β-cell function following administration to a type 2 diabetic HIV patient on antiretroviral therapy. ( Buysschaert, M; de la Tribonnière, X; Hermans, MP; Oriot, P; Selvais, P, 2011) |
| "A common variant in rs10494366 is associated with repaglinide monotherapy efficacy on insulin resistance in newly diagnosed Shanghai Chinese type 2 diabetes patients." | 7.76 | A variation in NOS1AP gene is associated with repaglinide efficacy on insulin resistance in type 2 diabetes of Chinese. ( Bao, YQ; Hu, C; Jia, WP; Lu, JY; Qin, W; Wang, CR; Xiang, KS; Yu, WH; Zhang, R, 2010) |
| "Repaglinide is an insulin secretagogue that often exhibits considerable interindividual variability in therapeutic efficacy." | 6.82 | A variation in KCNQ1 gene is associated with repaglinide efficacy on insulin resistance in Chinese Type 2 Diabetes Mellitus Patients. ( Adelusi, TI; Bao, Z; Li, W; Lu, Q; Lv, D; Shang, Z; Song, J; Sun, J; Wang, T; Wang, Y; Yin, X; Zhou, X; Zhu, J, 2016) |
| " Healthy volunteer studies have demonstrated a decrease in glucose disposal associated with dosing with specific antiretrovirals." | 6.75 | Effect of boosted fosamprenavir or lopinavir-based combinations on whole-body insulin sensitivity and lipids in treatment-naive HIV-type-1-positive men. ( Back, DJ; Boffito, M; Jackson, AG; Mandalia, S; Moyle, GJ; Randell, PA; Taylor, J; Tjia, JF, 2010) |
| " In this study, we used the frequently sampled intravenous glucose tolerance test (FSIGT) to evaluate the insulin sensitivity (IS), glucose sensitivity (SG), and acute insulin response after glucose load (AIRg) after 4 months treatment with either gliclazide or repaglinide." | 5.14 | Comparison of insulin sensitivity, glucose sensitivity, and first phase insulin secretion in patients treated with repaglinide or gliclazide. ( Chu, YM; Hsia, TL; Hsiao, FC; Hsieh, AT; Lee, LH; Lin, JD; Pei, C; Pei, D; Wang, K; Wu, CZ, 2010) |
| "In two separate double-blind, randomized, cross-over studies, we assessed the effects of a single dose of ritonavir (800 mg) and amprenavir (1200 mg) on insulin sensitivity (euglycemic hyperglycemic clamp) in healthy normal volunteers." | 5.12 | Effects of ritonavir and amprenavir on insulin sensitivity in healthy volunteers. ( Aweeka, F; Grunfeld, C; Lee, GA; Lo, JC; Mulligan, K; Rao, M; Schambelan, M; Schwarz, JM, 2007) |
| " We fed albino rats a high-fat fructose diet (HFFD) for 2 months to induce insulin resistance/type 2 diabetes and then treated the rats with ellagic acid (10 mg/kg body weight, orally) and/or repaglinide (0." | 3.85 | Estimation of ellagic acid and/or repaglinide effects on insulin signaling, oxidative stress, and inflammatory mediators of liver, pancreas, adipose tissue, and brain in insulin resistant/type 2 diabetic rats. ( Amin, MM; Arbid, MS, 2017) |
| " During the first year of treatment, exenatide, in combination with metformin and repaglinide, led to a weight loss of 14 kg and fat mass and waist circumference were respectively reduced from 31 to 25." | 3.77 | Exenatide improves weight loss insulin sensitivity and β-cell function following administration to a type 2 diabetic HIV patient on antiretroviral therapy. ( Buysschaert, M; de la Tribonnière, X; Hermans, MP; Oriot, P; Selvais, P, 2011) |
| "A common variant in rs10494366 is associated with repaglinide monotherapy efficacy on insulin resistance in newly diagnosed Shanghai Chinese type 2 diabetes patients." | 3.76 | A variation in NOS1AP gene is associated with repaglinide efficacy on insulin resistance in type 2 diabetes of Chinese. ( Bao, YQ; Hu, C; Jia, WP; Lu, JY; Qin, W; Wang, CR; Xiang, KS; Yu, WH; Zhang, R, 2010) |
| "Repaglinide is an insulin secretagogue that often exhibits considerable interindividual variability in therapeutic efficacy." | 2.82 | A variation in KCNQ1 gene is associated with repaglinide efficacy on insulin resistance in Chinese Type 2 Diabetes Mellitus Patients. ( Adelusi, TI; Bao, Z; Li, W; Lu, Q; Lv, D; Shang, Z; Song, J; Sun, J; Wang, T; Wang, Y; Yin, X; Zhou, X; Zhu, J, 2016) |
| "Both repaglinide and metformin were effective in glycaemic control in new onset patients with type 2 diabetes in China." | 2.79 | Comparison of metformin and repaglinide monotherapy in the treatment of new onset type 2 diabetes mellitus in China. ( Liao, Y; Liu, LY; Liu, W; Ma, J; Tao, T; Wu, PH, 2014) |
| " Healthy volunteer studies have demonstrated a decrease in glucose disposal associated with dosing with specific antiretrovirals." | 2.75 | Effect of boosted fosamprenavir or lopinavir-based combinations on whole-body insulin sensitivity and lipids in treatment-naive HIV-type-1-positive men. ( Back, DJ; Boffito, M; Jackson, AG; Mandalia, S; Moyle, GJ; Randell, PA; Taylor, J; Tjia, JF, 2010) |
| "Type 2 diabetes mellitus is characterised both by impaired release of insulin and by resistance to the action of insulin." | 2.41 | Early changes in beta-cell function and insulin pulsatility as predictors for type 2 diabetes. ( Pørksen, N, 2002) |
| "Type 2 diabetes is characterised by a progressive deterioration of the prandial insulin response, in a situation of continuing insulin resistance." | 2.41 | The importance of early insulin secretion and its impact on glycaemic regulation. ( Garber, AJ, 2000) |
| "While insulin resistance is common in older people, large numbers also have impaired insulin secretion." | 2.40 | The elderly Type 2 diabetic patient: special considerations. ( Morley, JE, 1998) |
| "Current agents for the treatment of Type 2 diabetes mellitus improve the metabolic profile but do not reinstate normality." | 2.40 | New agents for Type 2 diabetes. ( Bailey, CJ; Nattrass, M, 1999) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 4 (16.67) | 18.2507 |
| 2000's | 7 (29.17) | 29.6817 |
| 2010's | 12 (50.00) | 24.3611 |
| 2020's | 1 (4.17) | 2.80 |
| Authors | Studies |
|---|---|
| Abdel Moneim, A | 1 |
| Suleiman, HA | 1 |
| Mahmoud, B | 2 |
| Mabrouk, D | 1 |
| Zaky, MY | 1 |
| Huang, JF | 1 |
| Huang, CF | 1 |
| Yeh, ML | 1 |
| Dai, CY | 1 |
| Hsieh, MH | 1 |
| Yang, JF | 1 |
| Huang, CI | 1 |
| Lin, YH | 1 |
| Liang, PC | 1 |
| Lin, ZY | 1 |
| Chen, SC | 1 |
| Yu, ML | 1 |
| Chuang, WL | 1 |
| Liu, J | 1 |
| Cinar, R | 1 |
| Xiong, K | 1 |
| Godlewski, G | 1 |
| Jourdan, T | 1 |
| Lin, Y | 1 |
| Ntambi, JM | 1 |
| Kunos, G | 1 |
| Ma, J | 1 |
| Liu, LY | 1 |
| Wu, PH | 1 |
| Liao, Y | 1 |
| Tao, T | 1 |
| Liu, W | 1 |
| Haugaard, SB | 1 |
| Zhou, X | 1 |
| Zhu, J | 1 |
| Bao, Z | 1 |
| Shang, Z | 1 |
| Wang, T | 1 |
| Song, J | 1 |
| Sun, J | 1 |
| Li, W | 1 |
| Adelusi, TI | 1 |
| Wang, Y | 1 |
| Lv, D | 1 |
| Lu, Q | 1 |
| Yin, X | 1 |
| Amin, MM | 1 |
| Arbid, MS | 1 |
| Qin, W | 2 |
| Zhang, R | 2 |
| Hu, C | 2 |
| Wang, CR | 1 |
| Lu, JY | 1 |
| Yu, WH | 1 |
| Bao, YQ | 1 |
| Xiang, KS | 1 |
| Jia, WP | 1 |
| Wu, CZ | 1 |
| Pei, D | 1 |
| Hsieh, AT | 1 |
| Wang, K | 1 |
| Lin, JD | 1 |
| Lee, LH | 1 |
| Chu, YM | 1 |
| Hsiao, FC | 1 |
| Pei, C | 1 |
| Hsia, TL | 1 |
| Randell, PA | 1 |
| Jackson, AG | 1 |
| Boffito, M | 1 |
| Back, DJ | 1 |
| Tjia, JF | 1 |
| Taylor, J | 1 |
| Mandalia, S | 1 |
| Moyle, GJ | 1 |
| Yu, W | 1 |
| Wang, C | 1 |
| Lu, J | 1 |
| Jiang, F | 1 |
| Tang, S | 1 |
| Bao, Y | 1 |
| Xiang, K | 1 |
| Jia, W | 1 |
| Oriot, P | 1 |
| Hermans, MP | 1 |
| Selvais, P | 1 |
| Buysschaert, M | 1 |
| de la Tribonnière, X | 1 |
| Geffner, ME | 1 |
| Patel, K | 1 |
| Miller, TL | 1 |
| Hazra, R | 1 |
| Silio, M | 1 |
| Van Dyke, RB | 1 |
| Borkowsky, W | 1 |
| Worrell, C | 1 |
| DiMeglio, LA | 1 |
| Jacobson, DL | 1 |
| Pørksen, N | 1 |
| Blicklé, JF | 1 |
| Young, EM | 1 |
| Considine, RV | 1 |
| Sattler, FR | 1 |
| Deeg, MA | 1 |
| Buchanan, TA | 1 |
| Degawa-Yamauchi, M | 1 |
| Shankar, S | 1 |
| Edmondson-Melançon, H | 1 |
| Hernandez, J | 1 |
| Dubé, MP | 1 |
| Yan, Q | 1 |
| Hruz, PW | 1 |
| Lee, GA | 1 |
| Rao, M | 1 |
| Mulligan, K | 1 |
| Lo, JC | 1 |
| Aweeka, F | 1 |
| Schwarz, JM | 1 |
| Schambelan, M | 1 |
| Grunfeld, C | 1 |
| Morley, JE | 1 |
| Tack, CJ | 1 |
| Smits, P | 1 |
| Nattrass, M | 1 |
| Bailey, CJ | 1 |
| Garber, AJ | 1 |
| Kock, M | 1 |
| Calvo Romero, JM | 1 |
| Lima Rodríguez, EM | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Adolescent Master Protocol[NCT01418014] | 678 participants (Actual) | Observational | 2007-03-31 | Completed | |||
| [NCT00525239] | 60 participants (Anticipated) | Interventional | 2004-03-31 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
7 reviews available for carbamates and Insulin Resistance
| Article | Year |
|---|---|
Alteration in pancreatic islet function in human immunodeficiency virus.
Topics: Carbamates; Furans; HIV Protease Inhibitors; HIV-Associated Lipodystrophy Syndrome; Humans; Indinavi | 2014 |
Early changes in beta-cell function and insulin pulsatility as predictors for type 2 diabetes.
Topics: Carbamates; Circadian Rhythm; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Insulin; Insul | 2002 |
The elderly Type 2 diabetic patient: special considerations.
Topics: Aged; Amyloid; Blood Glucose; Carbamates; Cognition Disorders; Depression; Diabetes Mellitus, Type 2 | 1998 |
New drugs for diabetes.
Topics: Carbamates; Chromans; Cyclohexanes; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Insulin | 1999 |
New agents for Type 2 diabetes.
Topics: Anti-Obesity Agents; Carbamates; Chromans; Diabetes Mellitus, Type 2; Drug Design; Humans; Hypoglyce | 1999 |
The importance of early insulin secretion and its impact on glycaemic regulation.
Topics: Blood Glucose; Carbamates; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Eating; Humans; Hyp | 2000 |
[Objectives and therapeutic strategy in type 2 diabetes mellitus].
Topics: Carbamates; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Humans; Hyperinsulinism; Hypoglycemic | 2001 |
8 trials available for carbamates and Insulin Resistance
| Article | Year |
|---|---|
Viral clearance ameliorates hematological and inflammatory markers among diabetic patients infected with hepatitis C genotype 4.
Topics: Adult; Antiviral Agents; Biomarkers; Carbamates; Diabetes Mellitus, Type 2; Female; Genotype; Glycat | 2020 |
Comparison of metformin and repaglinide monotherapy in the treatment of new onset type 2 diabetes mellitus in China.
Topics: Body Mass Index; Carbamates; China; Combined Modality Therapy; Diabetes Mellitus, Type 2; Diet, Diab | 2014 |
A variation in KCNQ1 gene is associated with repaglinide efficacy on insulin resistance in Chinese Type 2 Diabetes Mellitus Patients.
Topics: Adult; Asian People; Carbamates; China; Diabetes Mellitus, Type 2; Female; Hep G2 Cells; Humans; Ins | 2016 |
Comparison of insulin sensitivity, glucose sensitivity, and first phase insulin secretion in patients treated with repaglinide or gliclazide.
Topics: Adult; Blood Glucose; Blood Pressure; Body Mass Index; Carbamates; Cross-Over Studies; Diabetes Mell | 2010 |
Effect of boosted fosamprenavir or lopinavir-based combinations on whole-body insulin sensitivity and lipids in treatment-naive HIV-type-1-positive men.
Topics: Adenine; Adipose Tissue; Adult; Anti-HIV Agents; Blood Glucose; Carbamates; Confidence Intervals; Dr | 2010 |
Effects of KCNQ1 polymorphisms on the therapeutic efficacy of oral antidiabetic drugs in Chinese patients with type 2 diabetes.
Topics: Administration, Oral; Adult; Alleles; Asian People; Blood Glucose; Carbamates; China; Diabetes Melli | 2011 |
Changes in thrombolytic and inflammatory markers after initiation of indinavir- or amprenavir-based antiretroviral therapy.
Topics: Adult; Biomarkers; Blood Glucose; Carbamates; Drug Therapy, Combination; Female; Fibrinolysis; Furan | 2004 |
Effects of ritonavir and amprenavir on insulin sensitivity in healthy volunteers.
Topics: Adult; Aged; Blood Glucose; Carbamates; Double-Blind Method; Energy Metabolism; Furans; Glucose Clam | 2007 |
9 other studies available for carbamates and Insulin Resistance
| Article | Year |
|---|---|
The outcomes of glucose abnormalities in chronic hepatitis C patients receiving interferon-free direct antiviral agents.
Topics: 2-Naphthylamine; Aged; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Therapy, Combinat | 2017 |
Monounsaturated fatty acids generated via stearoyl CoA desaturase-1 are endogenous inhibitors of fatty acid amide hydrolase.
Topics: Amidohydrolases; Analysis of Variance; Animals; Arachidonic Acids; Benzamides; Carbamates; Endocanna | 2013 |
Estimation of ellagic acid and/or repaglinide effects on insulin signaling, oxidative stress, and inflammatory mediators of liver, pancreas, adipose tissue, and brain in insulin resistant/type 2 diabetic rats.
Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Biomarkers; Brain; Carbamates; Diabetes Melli | 2017 |
A variation in NOS1AP gene is associated with repaglinide efficacy on insulin resistance in type 2 diabetes of Chinese.
Topics: Adaptor Proteins, Signal Transducing; Carbamates; China; Diabetes Mellitus, Type 2; Female; Humans; | 2010 |
Exenatide improves weight loss insulin sensitivity and β-cell function following administration to a type 2 diabetic HIV patient on antiretroviral therapy.
Topics: Adipose Tissue; Antiretroviral Therapy, Highly Active; Carbamates; Diabetes Mellitus, Type 2; Drug T | 2011 |
Factors associated with insulin resistance among children and adolescents perinatally infected with HIV-1 in the pediatric HIV/AIDS cohort study.
Topics: Adolescent; Body Mass Index; Carbamates; CD4 Lymphocyte Count; Child; Cohort Studies; Cross-Sectiona | 2011 |
[Type 2 diabetes mellitus pathogenesis: new therapeutic managements?].
Topics: Carbamates; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Ins | 2003 |
Direct comparison of the acute in vivo effects of HIV protease inhibitors on peripheral glucose disposal.
Topics: Adipocytes; Animals; Atazanavir Sulfate; Carbamates; Deoxyglucose; Dose-Response Relationship, Drug; | 2005 |
Insulin secretagogues.
Topics: Blood Glucose; Carbamates; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Insulin Resistanc | 1997 |